{"entity":{"id":"nct05400226","kind":"trial","name":"Phase 2 Study of VGT-309 in Lung Cancer","aka":[],"tldr":"A phase 2 trial of Abenacianine run by Vergent Bioscience, Inc., completed.","summary":"Phase 2 Study of VGT-309 in Lung Cancer is a phase 2 interventional study registered as NCT05400226 by Vergent Bioscience, Inc., with 40 participants enrolled, started 2022-05-24. Conditions recorded: Lung Cancer. Interventions recorded: VGT-309.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05400226","url":"https://clinicaltrials.gov/study/NCT05400226"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abenacianine"],"companies":["vergent-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05400226","phase":"2","setting":"A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Lung Cancer Surgery","sponsor":"Vergent Bioscience, Inc.","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05400226/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"drug":[{"id":"abenacianine","kind":"drug","name":"Abenacianine","route":"/drugs/abenacianine/"}],"company":[{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/"}]}}